NT 10-Q 1 angiosoma20190214_nt10q.htm FORM NT 10-Q angiosoma20181231_nt10k.htm



Washington, D.C. 20549



FORM 12b-25






(Check one):

☐ Form 10-K

☐ Form 20-F

☐ Form 11-K

☒ Form 10-Q

☐ Form 10-D

☐ Form N-SAR

☐ Form N-CSR




For Period Ended: December 31, 2018




☐  Transition Report on Form 10-K


☐  Transition Report on Form 20-F


☐  Transition Report on Form 11-K


☐  Transition Report on Form 10-Q


☐  Transition Report on Form N-SAR


For the Transition Period Ended:__________________________________


Nothing in this form shall be construed to imply that the Commission has verified any information contained herein.


If the notification relates to a portion of the filing checked above, identify the Item(s) to which the notification relates:




AngioSoma, Inc.


Full Name of Registrant




2500 Wilcrest Drive, 3rd Floor


Address of Principal Executive Office (Street and Number)




Houston, TX  77042


City, State and Zip Code






PART II — RULES 12b-25(b) AND (c)


If the subject report could not be filed without unreasonable effort or expense and the registrant seeks relief pursuant to Rule 12b-25(b), the following should be completed. (Check box if appropriate)




The reason described in reasonable detail in Part III of this form could not be eliminated without unreasonable effort or expense


The subject annual report, semi-annual report, transition report on Form 10-K, Form 20-F, Form 11-K, Form N-SAR or Form N-CSR, or portion thereof, will be filed on or before the fifteenth calendar day following the prescribed due date; or the subject quarterly report or transition report on Form 10-Q, or subject distribution report on Form 10-D,or portion thereof, will be filed on or before the fifth calendar day following the prescribed due date; and



The accountant’s statement or other exhibit required by Rule 12b-25(c) has been attached if applicable.




The report of the registrant on Form 10-Q for the quarter ended December 31, 2018 could not be filed within the prescribed time period because the Company needs additional time to complete the financial statements and to prepare the Form 10-Q. The registrant anticipates that it will require no more than the additional 5 days allowed to complete and file the Form 10-Q.





Name and telephone number of person to contact in regard to this notification



Alex K. Blankenship








(Area Code)


(Telephone Number)



Have all other periodic reports required under Section 13 or 15(d) of the Securities Exchange Act of 1934 or Section 30 of the Investment Company Act of 1940 during the preceding 12 months or for such shorter period that the registrant was required to file such report(s) been filed? If answer is no, identify report(s).


  ☒  Yes

  ☐  No



Is it anticipated that any significant change in results of operations from the corresponding period for the last fiscal year will be reflected by the earnings statements to be included in the subject report or portion thereof?


  ☐  Yes

  ☒  No



If so, attach an explanation of the anticipated change, both narratively and quantitatively, and, if appropriate, state the reasons why a reasonable estimate of the results cannot be made.







AngioSoma, Inc.


(Name of Registrant as Specified in Charter)


has caused this notification to be signed on its behalf by the undersigned hereunto duly authorized.




February 15, 2019



/s/ Alex K. Blankenship





Alex K. Blankenship, Chief Executive Officer